Medical Condition News

RSS

Newly-discovered watchmen DCs instruct T cells to attack and destroy cancer cells

Cancer Research UK scientists have discovered sophisticated 'watchman' cells in humans that can instruct the immune system to destroy foreign invaders like viruses and cancer cells, according to research published in The Journal of Experimental Medicine.

19 May 2010

Aprea to present poster on phase I/II clinical trial of APR-246 anticancer compound at ASCO Meeting

Among more than 5000 poster abstracts, Aprea AB has been selected to present a poster at the annual American Society of Clinical Oncology (ASCO) Meeting in Chicago. The presentation will describe the scientific rational and design of the ongoing phase I/II clinical trial with Aprea's drug candidate APR-246.

19 May 2010

NAC therapy shows promise for patients with mild IPF

A new therapy shows promise for patients with mild idiopathic pulmonary fibrosis. According to researchers in Japan, inhaled N-acetylcysteine monotherapy preserves more lung function in some idiopathic pulmonary fibrosis patients than no therapy.

19 May 2010

Oncolytics announces publication of Phase Ia/Ib U.K. clinical trial results of REOLYSIN for cancer

Oncolytics Biotech Inc. announced today that a paper entitled "Two-Stage Phase I Dose-Escalation Study of Intratumoural Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers," has been published in the online version of the journal Clinical Cancer Research.

19 May 2010

Causes and treatment options of mental disorders need to be reassessed: JAMA commentary

It is time to reassess mental disorders, recognizing that these are disorders of brain circuits likely caused by development processes, according to a commentary in the May 19 issue of JAMA, a theme issue on mental health.

19 May 2010

Lentigen receives NIH STTR grant for Hunter syndrome lentiviral gene therapy

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business technology transfer (STTR) grant for a program on "Lentiviral Gene Therapy for Mucopolysaccharidosis."

19 May 2010

Researchers discover biological pathway signature of ccRCC

By examining expression of every human gene in clear cell renal cell carcinoma compared to normal kidney cells, researchers at Mayo Clinic's campus in Florida have discovered gene signatures they say explain much of the biology of this common and difficult-to-treat kidney cancer.

19 May 2010

Majority of patients experience depression following hospitalization for TBI: Study

During the year following hospitalization for a traumatic brain injury, a majority of patients experienced major depression, according to a study in the May 19 issue of JAMA, a theme issue on mental health.

19 May 2010

30 percent risk of heart attack in Australians over 55

According to a new study researchers have warned that at least one in five Australians over the age of 55 have a 30 percent chance of suffering a potentially fatal heart attack or stroke in the next five years.

18 May 2010

Repetitive treatment with cocktail of B vitamins improve recovery after TBI

Hard to Treat Diseases, Inc. is pleased to announce the second poster presentation researchers from its Slavica BioChem division have presented at the 8th World Congress on the Brain Injury, held in Washington, DC, March 10-14, 2010, under the auspices of The International Brain Injury Association.

18 May 2010

Senesco to present preclinical data of SNS-01 at ASGCT Annual Meeting

Senesco Technologies, Inc. today announced that preclinical data for the Company's lead drug candidate, SNS-01, will be presented on May 20, 2010 at the American Society of Gene and Cell Therapy Annual Meeting being held at the Marriott Wardman Park Hotel in Washington, D.C. from May 17 to 22.

18 May 2010

FDA grants orphan drug designation to pralatrexate for treatment of advanced TCC of urinary bladder

Allos Therapeutics, Inc. announced today that the U.S. Food and Drug Administration has granted orphan drug designation to pralatrexate for the treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder, a form of bladder cancer. The Company is currently investigating pralatrexate in a Phase 2 clinical study in patients with advanced or metastatic relapsed TCC of the urinary bladder.

18 May 2010

Warnings about a ruined appearance is best way to reduce tanning salon visits

What's the most effective way to convince young women to cut back on their indoor tanning, a habit that hikes their risk of melanoma, the deadliest form of skin cancer, by 75 percent? Warn them that it will cause leathery, wrinkled skin.

18 May 2010

Interphone Study underestimates risk of brain cancer, says International EMF Collaborative

Authors of the report, "Cellphones and Brain Tumors: 15 Reasons for Concern, Science, Spin and the Truth Behind Interphone" have released a technical analysis of the long-awaited Interphone Study published today in the International Journal of Epidemiology.

18 May 2010

ICF International awarded multi-year contract to support community action in reducing chronic disease

ICF International, a leading provider of consulting services and technology solutions to government and commercial clients, has been awarded a new $11.6 million multi-year contract by the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, to develop a resource center for broad-scale community action to reduce chronic disease.

18 May 2010

Web conference to analyze latest trends, developments in the European melanoma skin cancer market

There are only two FDA/EMEA approved drugs currently available for treating advanced melanoma. The available drugs, however, are not completely effective and have adverse effects. Unmet needs of patients, especially those with advanced melanoma are therefore quite high and have led to a low drug adoption and market growth over the years. The future looks brighter though, with a few promising drugs in pipeline for advanced melanoma.

18 May 2010

Human stem cells restore alveolar epithelial tissue after E. coli endotoxin-induced ALI: Researchers

Human stem cells administered intravenously can restore alveolar epithelial tissue to a normal function in a novel ex vivo perfused human lung after E. coli endotoxin-induced acute lung injury, according to research from the University of California San Francisco.

18 May 2010

Study reveals association between depression and coronary spasm

A study published in the current issue of Psychotherapy and Psychosomatics explores the relationship between depression and coronary artery spasm.

18 May 2010

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

Dr. Bruce Bode announced today that he is now recruiting adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes.

18 May 2010

KemPharm enters Supply Agreement with Johnson Matthey for KP201 hydrocodone prodrug for acute pain

KemPharm, Inc. today announced that it has entered into an exclusive Supply Agreement with Johnson Matthey Inc., for the manufacture of the active pharmaceutical ingredient (API), KP201, KemPharm's novel hydrocodone prodrug for acute pain. KP201 was identified utilizing KemPharm's proprietary ligand activated therapy (LAT) approach.

18 May 2010

Medical Condition News

Newly-discovered watchmen DCs instruct T cells to attack and destroy cancer cells

Aprea to present poster on phase I/II clinical trial of APR-246 anticancer compound at ASCO Meeting

NAC therapy shows promise for patients with mild IPF

Oncolytics announces publication of Phase Ia/Ib U.K. clinical trial results of REOLYSIN for cancer

Causes and treatment options of mental disorders need to be reassessed: JAMA commentary

Lentigen receives NIH STTR grant for Hunter syndrome lentiviral gene therapy

Researchers discover biological pathway signature of ccRCC

Majority of patients experience depression following hospitalization for TBI: Study

30 percent risk of heart attack in Australians over 55

Repetitive treatment with cocktail of B vitamins improve recovery after TBI

Senesco to present preclinical data of SNS-01 at ASGCT Annual Meeting

FDA grants orphan drug designation to pralatrexate for treatment of advanced TCC of urinary bladder

Warnings about a ruined appearance is best way to reduce tanning salon visits

Interphone Study underestimates risk of brain cancer, says International EMF Collaborative

ICF International awarded multi-year contract to support community action in reducing chronic disease

Web conference to analyze latest trends, developments in the European melanoma skin cancer market

Human stem cells restore alveolar epithelial tissue after E. coli endotoxin-induced ALI: Researchers

Study reveals association between depression and coronary spasm

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

KemPharm enters Supply Agreement with Johnson Matthey for KP201 hydrocodone prodrug for acute pain

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Latest News